



April 24, 2026

To whom it may concern:

Company name KISSEI PHARMACEUTICAL CO., LTD.
 Representative Mutsuo Kanzawa, Chairman and CEO
 (Stock code 4547; Prime Market, Tokyo
 Stock Exchange)
 Contact Kazuya Uchimura, Senior Director,
 Public Relations Department
 (Telephone +81-263-25-9523)

Kissei Announces New President and COO

At the meeting of our Company's Board of Directors on April 24, 2026, a decision was made to change the President as follows.

This change will be authorized at the regular shareholders' meeting and at the meeting of Board of Directors, both scheduled for June 23, 2026.

1. Reason for Change

Kissei will further strengthen its management structure in order to achieve its medium-term management plan, Beyond 80, which was launched in April of last year.

2. New Roles

New Title	Name	Current Title
President and COO	Keiji Miyazawa	Member of the Board, Division Director of Research Division, and KISSEI AMERICA, INC. Director
Adviser	Yasuo Takehana	President and COO

3. Resume of the new President

Name	Resume	Shares held
Keiji Miyazawa (DOB: April 14, 1967)	April 1993 Joined the Company	4,407 shares
	October 2017 Director of Business Development Department	
	April 2018 Director of Research Strategy and Planning Department, Research Division	
	April 2019 Director of Research Strategy and Planning Department, Drug Discovery Strategy Division	
	September 2021 Senior Director of Research Strategy and Planning Department, Research Division	
June 2022 Member of the Board, Division Director of Research Division, and KISSEI AMERICA, INC. Director (current position)		

4. Effective date: June 23, 2026